Abstract: The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.
Abstract: Disclosed in the present invention are a crystal form of a TrkA inhibitor and a preparation method thereof, and an application thereof in preparation of drugs for treating diseases associated with pain, cancer, inflammation, neurodegenerative diseases, and certain infectious diseases.
Abstract: Disclosed is a method for preparing a pyrrolidinyl urea derivative, which acts as a TrkA inhibitor, and further disclosed are an intermediate compound of a compound of formula (I) and a preparation method therefor.
Abstract: A crystal form of a pyrazin-2(1H)-one compound and a preparation method therefor. The present invention specifically related to a compound of formula (II) and a preparation method for a crystal form of the compound.
Abstract: Disclosed are a crystal form of a thieno[2,3-c]pyridazine-4(1H)-one compound, a preparation method therefor and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2.
Abstract: Disclosed in the present invention are a crystal form of a TrkA inhibitor and a preparation method therefor, and an application thereof in preparation of drugs for treating diseases associated with pain, cancer, inflammation, neurodegenerative diseases, and certain infectious diseases.
Abstract: Provided are crystalline forms of pyrazine-2(1H)-ketone compound and a preparation method thereof; specifically disclosed are a method for preparing the compound of formula (II) and crystalline forms thereof.
Abstract: The present invention disclosed a crystal form of pyrazine-2(1H)-ketone compound and a preparation method therefor. Specifically disclosed is a method for preparing a compound of formula (II) and a crystal form thereof.
Abstract: Disclosed are a crystal form (I) as an inhibitor of ACC1 and ACC2, a preparation method therefor, and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2.
Abstract: Disclosed are a crystal form (I) as an inhibitor of ACC1 and ACC2, a preparation method therefor, and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2.
Abstract: Disclosed is a total flavonoids extract of Gynura formosana Kitam., containing 80%-85% of rutin by weight percent content. The results of pharmacological experiments show that the extract can lower the activity of xanthine oxidase in the liver of a hyperuricemia model mouse and reduce the synthesis of uric acid to a certain degree and has a certain uric acid-lowering effect, and can be used as a potential drug for treating hyperuricemia or gout. The method for preparing the total flavonoids extract of Gynura formosana Kitam. comprises: after an extraction step, selecting a complex enzyme composed of enzymes with a specific composition and a specific ratio for enzymolosis, and further carrying out the step of extracting and concentrating with macroporous resin and isolating and purifying with macroporous resin, so that the HPLC purity of rutin in the resulting total flavonoids extract of Gynura formosana Kitam. reaches 80%-85%.
Abstract: Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases.
Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease.
Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease.
Abstract: A total flavonoid extract from Gynura formosana Kitam., comprising, in weight percent, 80-85% of rutin. A method for preparing the total flavonoid extract from Gynura formosana Kitam. comprises solvent extraction, complex enzymatic hydrolysis, and separation and purification by a macroporous resin. The total flavonoid extract from Gynura formosana Kitam. is used to prepare a drug or health product related to alcoholic fatty liver disease.
Abstract: The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.
Abstract: Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases.
Abstract: A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively.
Abstract: A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a pharmaceutically acceptable salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively.